Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedLipoglycopeptideFDA-approved 2014 · DalvanceHalf-life ~8.5 days

Dalbavancin

A skin-infection antibiotic that can be a single infusion

Dalbavancin is a lipoglycopeptide antibiotic: a natural glycopeptide modified with a fatty tail that anchors it in membranes and plasma proteins. Its effective half-life of about 8.5 days means a course of treatment can be one infusion, or two a week apart.

Manufacturer's recommended dosing (FDA label): 1,500 mg once, or 1,000 mg then 500 mg one week later, Single or two-dose regimen, Intravenous, over 30 minutes Details ↓

Overview

What is it?

Glycopeptide antibiotics such as vancomycin kill Gram-positive bacteria by binding the building blocks of their cell wall. Dalbavancin adds a lipid side chain, which anchors it in the bacterial membrane and binds it to plasma proteins, giving an effective half-life of about 8.5 days. The practical consequence is a course that takes one or two visits rather than a week or more of daily infusions.

The DISCOVER 1 and DISCOVER 2 trials pooled 1,312 patients with skin infections: early clinical response was 79.7% on dalbavancin and 79.8% on vancomycin followed by linezolid. Among patients with Staphylococcus aureus, including MRSA, clinical success was 90.6% and 93.8%. The label offers 1,500 mg once, or 1,000 mg followed a week later by 500 mg, infused over 30 minutes, with lower doses when creatinine clearance is under 30 mL/min and the patient is not on dialysis.

The DOTS trial moved it into bloodstream infection: two doses a week apart after initial therapy for complicated S. aureus bacteraemia, compared with standard antibiotics. Its pharmacokinetic analysis found low clearance that rises modestly with kidney function, and its economic analysis found about 24 fewer days of antibiotics. In Canadian practice, it is mostly given because it is a single dose or lets patients go home sooner. A 2026 systematic review of 21 studies found high success in bone, bloodstream and heart-valve infections in observational data, but lower effectiveness in biofilm infections where the source was not controlled, and consistent reductions in hospital stay.

Its label warns of hypersensitivity, infusion-related reactions, liver effects and Clostridioides difficile diarrhoea. A pooled safety analysis found lower rates of kidney toxicity than with at least 10 days of intravenous vancomycin (3.7% against 9.3%). Long courses carry a cost: after prolonged treatment for joint infections, a fifth of patients carried resistant skin staphylococci.

Children are covered by the approval for skin infections, at 22.5 mg/kg under 6 years and 18 mg/kg from 6 to 17, up to 1,500 mg. In the paediatric study, clinical response was assessed from 48 hours to 54 days after treatment, and audiology and bowel flora were checked in a subset; off-label use for bone and heart infections in children has been reported with good results in small series.

1 dose
1,500 mg covers a skin infection
Dalvance label 2.1
79.7% vs 79.8%
Early response vs vancomycin-linezolid
DISCOVER, 1,312 patients · PMID 24897082
~8.5 days
Effective half-life
Label 12.3
Science

Mechanism of Action

Dalbavancin is a lipoglycopeptide: it blocks cell-wall building like vancomycin and lasts long enough for a one- or two-dose course.

🧱

Cell-wall precursors

Binds the D-alanyl-D-alanine end of cell-wall precursors, stopping peptidoglycan assembly.

⚓

Membrane anchor

A lipid side chain anchors it to the bacterial membrane and binds plasma proteins.

⏱️

Very long half-life

Effective half-life about 8.5 days, terminal about 346 hours (label 12.3).

Evidence

Published Research

The studies behind dalbavancin, from their PubMed abstracts.

Human2014

DISCOVER 1 and 2: once-weekly against daily therapy

In the pooled analysis of 1,312 patients with skin infections, early clinical response was 79.7% on dalbavancin and 79.8% on vancomycin-linezolid, meeting noninferiority; with S. aureus, including MRSA, success was 90.6% against 93.8%.

PMID: 24897082
Human2025

DOTS: Staphylococcus aureus in the bloodstream

In 200 participants, the probability of a more desirable day-70 outcome with dalbavancin against standard therapy was 47.7%; clinical efficacy was documented in 73 of 100 and 72 of 100, meeting noninferiority, with serious adverse events in 40 and 34.

PMID: 40802264
Human2021

Kidney safety against vancomycin

Among 1,325 patients on any dalbavancin regimen, kidney toxicity occurred in 3.7%, against 9.3% of 54 patients given intravenous vancomycin for at least 10 days.

PMID: 33515414
Human2023

Children with skin infections

In a phase 3 open-label study, children from birth to under 18 received single-dose or two-dose dalbavancin or a comparator antibiotic; treatment-emergent adverse events occurred in 7.2% and 9.0% of the dalbavancin groups and 3.3% of comparator patients.

PMID: 36476623
Human2026

Pharmacokinetics in the DOTS trial

In 97 patients with complicated Staphylococcus aureus bacteraemia, clearance was low (0.066 L/h) with about 23% variability between patients, rose with kidney function and volume rose with body weight.

PMID: 41999282
Human2026

Costs in the DOTS trial

In the DOTS trial of S. aureus bacteraemia, patients randomised to dalbavancin received antibiotics on 24.4 fewer days; higher drug costs were offset by lower outpatient-infusion costs, for a net saving of about $5,900 that was not statistically certain.

PMID: 42752824
Human2026

How Canada uses it

In the Canadian CLEAR registry, dalbavancin was used mostly for skin infections (55.6%) and bone and joint infections (24.4%), most often against MRSA, and chosen mainly because it was a single dose or allowed earlier discharge.

PMID: 42788820
Human2026

Resistance after long courses

Among 19 patients given long-term dalbavancin for prosthetic joint infection, 4 carried dalbavancin-resistant Staphylococcus epidermidis on the skin or in the nose, against none in untreated controls.

PMID: 42372046
Human2026

Off-label use in children

In seven children aged 5 to 17 treated off label for bone, heart-valve and device infections, all were cured without relapse and no adverse events were attributed to dalbavancin; a review of ten studies accompanied the series.

PMID: 42572145
Human2026

Bone and joint infections: 101 patients with drug-level monitoring

In 101 outpatients with chronic bone and joint infections given dalbavancin on a schedule adjusted by blood-level monitoring (418 doses), the target level was reached in 89.6% of doses, 75.3% of those who finished treatment improved or were cured, and 3% stopped for adverse events; this use is off-label.

PMID: 42405345
Human2026

Osteomyelitis without implants: a hospital's records

Of 157 patients given dalbavancin at one Italian hospital, mostly off-label and often to allow earlier discharge, treatment succeeded in 90.7% of 43 with osteomyelitis without implants and 81.1% of 53 with skin infections; older age raised the risk of failure.

PMID: 42505603
Review2026

Real-world use: 21 studies reviewed

A systematic review of randomised and observational studies confirmed non-inferiority in skin infections and found high success in bone, bloodstream and endocarditis cases, lower effectiveness in biofilm infections without source control, and shorter hospital stays.

PMID: 42197456
Review2025

Bone and joint infections pooled

Across 6 studies of 581 patients, only one randomised, dalbavancin was as successful as standard care for bone and joint infection (odds ratio 1.55, not significant) and four studies found shorter hospital stays. It is not a labelled use.

PMID: 39029624
Dosing

Dosing Data

Dalvance is infused over 30 minutes as a single 1,500 mg dose or as 1,000 mg then 500 mg a week later; doses are lower in severe kidney impairment off dialysis, and weight-based in children.

Prescription antibiotic infused in hospital or clinic; infusion reactions and hypersensitivity are the main warnings.
ProtocolDoseFrequencyDurationRoute
Label: adults, CrCl ≥30 mL/min or on haemodialysis Approved labelDalvance (dalbavancin) for injection US prescribing information (DailyMed set 4b4674d8, effective January 13, 2025)1,500 mg once, or 1,000 mg then 500 mg one week laterSingle or two-dose regimenCourse completeIntravenous, over 30 minutes
Label: adults, CrCl <30 mL/min not on haemodialysis Approved labelDalvance (dalbavancin) for injection US prescribing information (DailyMed set 4b4674d8, effective January 13, 2025)1,125 mg once, or 750 mg then 375 mg one week laterSingle or two-dose regimenCourse completeIntravenous, over 30 minutes
Label: children, CrCl ≥30 mL/min/1.73m² Approved labelDalvance (dalbavancin) for injection US prescribing information (DailyMed set 4b4674d8, effective January 13, 2025)22.5 mg/kg (birth to <6 y) or 18 mg/kg (6 to <18 y), max 1,500 mgSingle doseCourse completeIntravenous, over 30 minutes

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

One or two infusions
Dalbavancin is a fixed adult dose adjusted only for severe kidney impairment, or mg/kg in children; the pharmacy reconstitutes and dilutes it.
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

Source: Dalvance (dalbavancin injection) label, section 3 (DailyMed version 29, effective January 13, 2025).

Mixing a vial: a worked example

Nothing to mix at home, and no syringe units to work out: Dalbavancin is prepared and given by clinical staff, in hospital or an infusion clinic.

Its US label gives it as a 30-minute infusion into a vein from a vial that is dissolved and then diluted into an infusion bag.

Source: Dalvance (dalbavancin injection) label, section 2 (DailyMed version 29, effective January 13, 2025).

Storage before and after mixing

Before mixing or first use: the label sentences we read do not say.

After mixing or first use: “Reconstituted vials may be stored either refrigerated at 2°C to 8°C (36°F to 46°F), or at controlled room temperature 20°C to 25°C (68°F to 77°F).” “Once diluted into an intravenous bag or bottle as described above, DALVANCE may be stored either refrigerated at 2°C to 8°C (36°F to 46°F) or at a controlled room temperature of 20°C to 25°C (68°F to 77°F).” “Discard any unused portion of the reconstituted solution.”

Source: Dalvance (dalbavancin injection) label, sections 16 and 2 (DailyMed version 29, effective January 13, 2025).

How it is taken

As the approved label gives it: Intravenous, over 30 minutes (Single or two-dose regimen; Label: adults, CrCl ≥30 mL/min or on haemodialysis).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of effective half-life about 8.5 days (204 hours); terminal half-life about 346 hours. After about five half-lives almost none is left.

How long the doses were given: Label: adults, CrCl ≥30 mL/min or on haemodialysis: Course complete; Label: adults, CrCl <30 mL/min not on haemodialysis: Course complete; Label: children, CrCl ≥30 mL/min/1.73m²: Course complete.

When effects appear: unknown; no source on this page gives a time to effect for Dalbavancin. Results reported in the studies are under Published Research.

Source: half-life: Dalvance prescribing information, section 12.3 (DailyMed set 4b4674d8, effective January 13, 2025); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Lower rates of kidney toxicity than prolonged intravenous vancomycin; Serious adverse events in 40% against 34% on standard therapy in the bloodstream-infection trial. Full list and cautions ↓

When the label says to stop or get help:

  • Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE. If an allergic reaction occurs, discontinue treatment with DALVANCE and institute appropriate therapy for the allergic reaction. Carefully monitor patients with known hypersensitivity to glycopeptides.

Source: Dalvance (dalbavancin injection) label, boxed warning and section 5 (DailyMed version 29, effective January 13, 2025); the Side Effects section below (“From the studies above”).

Interactions

Every peptide's record, with its source: the interaction matrix.

Source: AbbVie. DALVANCE (dalbavancin) for injection, US prescribing information, section 7. DailyMed version effective January 13, 2025, read October 3, 2026.

Checking what you bought

Unknown: no published independent test of Dalbavancin products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Dalvance (now AbbVie), NDA 021883, on May 23, 2014, for acute bacterial skin and skin structure infections). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Lower rates of kidney toxicity than prolonged intravenous vancomycin
● Serious adverse events in 40% against 34% on standard therapy in the bloodstream-infection trial

Contraindications & Cautions

Warnings from the Dalvance label (DailyMed, effective January 13, 2025).

● Hypersensitivity reactions
● Infusion-related reactions
● Liver effects
● Clostridioides difficile-associated diarrhoea
● Development of drug-resistant bacteria
Questions

Frequently Asked Questions

?Is dalbavancin a peptide?

Yes, in the broad sense: it is a glycopeptide, a peptide core carrying sugars, modified with a fatty side chain, which is why the class is called lipoglycopeptides.

?How long does one dose of dalbavancin last?

Its effective half-life is about 8.5 days, which is why a skin infection can be treated with a single 1,500 mg infusion or two doses a week apart.

?What is dalbavancin used for?

Acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, in adults and children. It has also been studied for bloodstream infection.

?Can it treat bloodstream infections?

Not on the label, which covers skin infections. The DOTS trial tested two doses a week apart after initial therapy for complicated S. aureus bacteraemia, and observational studies report high success in bone and heart-valve infections.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): DALVANCE, NDA 021883 (May 23, 2014). Read October 3, 2026.
  2. [fda-pi] FDA. Dalvance (dalbavancin) US prescribing information (DailyMed set 4b4674d8-4d1e-4728-8465-d42ada33fa5c, version 29, effective January 13, 2025). Read October 3, 2026.
  3. [clinical-trial] Boucher HW, et al. "Once-weekly dalbavancin versus daily conventional therapy for skin infection." N Engl J Med, 2014;370(23):2169-79. PMID: 24897082.
  4. [clinical-trial] Turner NA, et al. "Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial." JAMA, 2025;334(10):866-77. PMID: 40802264.
  5. [pubmed] Gonzalez PL, et al. "Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials." Infect Dis Ther, 2021;10(1):471-481. PMID: 33515414.
  6. [pubmed] Giorgobiani M, et al. "The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections." Pediatr Infect Dis J, 2023;42(3):199-205. PMID: 36476623.
  7. [pubmed] Almangour TA, et al. "Dalbavancin for the treatment of bone and joint infections: A meta-analysis." J Infect Chemother, 2025;31(1):102473. PMID: 39029624.
  8. [clinical-trial] Lodise TP, et al. "Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial." JAMA Netw Open, 2026;9(4):e2611652. PMID: 41999282.
  9. [pubmed] Reed SD, et al. "Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial." Clin Infect Dis, 2026. PMID: 42752824.
  10. [pubmed] Zhanel GG, et al. "Clinical use of dalbavancin in Canada: the CLEAR study final results." Expert Rev Anti Infect Ther, 2026:1-9. PMID: 42788820.
  11. [pubmed] Hugg R, et al. "Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections." J Antimicrob Chemother, 2026;81(7). PMID: 42372046.
  12. [pubmed] Domínguez-León V, et al. "Expanding the Role of Dalbavancin in Children: A Case Series and Systematic Review." Pediatr Infect Dis J, 2026. PMID: 42572145.
  13. [fda-pi] Dalvance (dalbavancin) for injection US prescribing information (DailyMed set 4b4674d8, version 29, effective January 13, 2025), sections 2.1-2.3; read through openFDA October 6, 2026.
  14. [pubmed] Tana C, et al. "Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies." Microorganisms, 2026;14(5). PMID: 42197456.
  15. [pubmed] Rabbione A, et al. "A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians)." JAC Antimicrob Resist, 2026;8(4):dlag127. PMID: 42405345.
  16. [pubmed] Tiecco G, et al. "Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study." Antibiotics (Basel), 2026;15(7). PMID: 42505603.

Sources & Citations

Studies were read from their PubMed abstracts; the Dalvance label from DailyMed (set 4b4674d8, effective January 13, 2025) through openFDA, read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-16